健择在晚期软组织肉瘤二线治疗中的作用  

The Effect of Gemcitabine on Second- line Treatment for Patients with Advanced Soft Tissue Sarcomas

作　　者：张荣生[1] 刘叙仪[2] 

机构地区：[1]大理学院附属医院内科,云南大理671000 [2]北京大学临床肿瘤学院内科,北京100036

出　　处：《大理学院学报（综合版）》2004年第5期91-94,共4页Journal of Dali University

摘　　要：目的 :评价健择治疗晚期软组织肉瘤以阿霉素和异环磷酰胺为基础化疗失败的病人。方法 :对国内外文献进行归纳、分析及总结。结果 :系统阐述该领域在国内外研究现状 ,为今后研究起到指导作用。结论 :健择在晚期软组织肉瘤二线治疗中有较好疗效、化疗毒性可耐受。Objective:To assess the efficacy of gemcitabine in patients with a Variety of advanced soft tissue Sarcomas that have failed to respond or escaped Adriamycin- and ifosfamide- based chemotherapy.Methods:The data of domestic and foreign records were collected and summarized.Results:We systematically elaborated domestic and foreign states about the study,It will guide the further research.Conclusions:The gemcitabine is a highly effective regimen for patients with a variety of advanced soft tissue sarcomas that have failed to respond or escaped Adriamycin- and ifosfamide- based chemotherapy with a manageable toxicity.

关 键 词：晚期软组织肉瘤 药物治疗 健择 阿霉素 异环磷酰胺 

分 类 号：R730.269[医药卫生—肿瘤]